0001209191-23-000009.txt : 20230103
0001209191-23-000009.hdr.sgml : 20230103
20230103075727
ACCESSION NUMBER: 0001209191-23-000009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221230
FILED AS OF DATE: 20230103
DATE AS OF CHANGE: 20230103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cook Timothy DeVere
CENTRAL INDEX KEY: 0001902974
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38112
FILM NUMBER: 23500232
MAIL ADDRESS:
STREET 1: C/O ATHENEX, INC., 1001 MAIN STREET,
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athenex, Inc.
CENTRAL INDEX KEY: 0001300699
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 431985966
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
BUSINESS PHONE: 716-898-8625
MAIL ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20131223
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC
DATE OF NAME CHANGE: 20040817
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-30
0
0001300699
Athenex, Inc.
ATNX
0001902974
Cook Timothy DeVere
C/O ATHENEX, INC., 1001 MAIN STREET
SUITE 600
BUFFALO
NY
14203
0
1
0
0
See Remarks
Common Stock
2022-12-30
4
A
0
3390
0.1475
A
36079
D
Stock Option (Right to Buy)
17.29
2022-08-16
2028-08-16
Common Stock
70000
70000
D
Stock Option (Right to Buy)
10.26
2030-08-27
Common Stock
30000
30000
D
Stock Option (Right to Buy)
3.56
2031-09-16
Common Stock
9000
9000
D
Restricted Stock Units
Common Stock
6750
6750
D
Stock Option (Right to Buy)
0.6655
2032-07-20
Common Stock
75000
75000
D
Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
This option vests in four equal annual installments beginning on August 27, 2021.
This option vests in four equal annual installments beginning on September 16, 2022.
Each restricted stock unit represents a contingent right to receive one share of stock.
The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
This option vests in four equal annual installments beginning on July 20, 2023.
Chief Business and Commercial Officer, Proprietary Drugs
/s/Steven Adams, Attorney-in-Fact
2023-01-03